Maunzaro was launched in India in March. Wagovi has been launched in the last week of June. These weight loss drugs of Novo and Lily help control blood sugar and slow down digestion, which makes the stomach feel full for a long time and people eat less. Now how many obesity people are using in India. In such a situation, let us know how effective the doctors have these medicines. Also, how can these medicines affect health.
Online database and analytical tools pharmotrac which gives information about the Indian pharmaceutical market. According to its data, Maunzaro, a drug control of treatment and obesity of type-2 diabetes, has gained rapid popularity in India. Within just three months of its launch in March 2025, its sales have been recorded at Rs 50 crore. The Vice President (Commerce) of the Farmarack Sheetal Saple says that the availability of new drugs for obesity and the desire to try them has promoted market growth.
According to the report, the monthly sales of Maunzaro increased from Rs 13 crore in May to Rs 26 crore in June. Since the launch, the sales of Maunzaro increased by more than 7 times. In March and May, 81,570 Maunjaro units were sold and in June alone they reached 87,986 units.
The price of Vegovi and Maunzaro is between Rs 17,000 to Rs 26,000 per month. Due to which most of the Indians with insurance or heavy pockets are out of reach. However, due to high price, India’s middle class families did not diminish enthusiasm for weight loss medicines. Doctors across the country said that they are now getting more patients who are questioning about this and demand.
Many companies on the way to come
Indian pharmaceutical companies like Sun Pharma, Cipla, Dr. Reddy’s, Lupine and Biocon are preparing to launch cheap generic medicines, which will hit the global market map of Rs 12,450 billion ($ 150 billion) in the next 10 years.
According to Reuters Health Rounds, research has shown that the effectiveness of these weight losss in real life is less than tests. Apart from this, the World Health Organization had said at the end of last year that these drugs are ‘likely to eliminate obesity epidemic’ but from these people who do not have the proper means (money) to take these treatment. In such a situation, they can have a negative effect.
Both the silence and vegovi present in India work by mimicking a natural hormone (insulin) that controls blood sugar and hunger, which improves glycemic control and loses weight. These are given through the injection under the skin once a week. These medicines have proved to be effective in reducing body weight to a lot of Haj, controlling blood sugar, delaying the stomach vacancy and making the stomach full.
Apart from weight loss, they also reduce the risk of heart events in people with type 2 diabetes. Vagovi can be prescribed to lose weight in adults, especially obese -suffering from obesity. Maunzaro targets both hormones controlling blood sugar and reducing appetite, which improves glycemic control and reduces weight.
How does silence work?
Maunzaro helps in weight loss and control of type 2 diabetes in association with diet and exercise. It affects the body in three major ways. Insulin increases secretion, which leads to blood sugar control. Insulin improves sensitivity to react better to insulin. Reduces appetite, which makes the stomach feel full, which reduces the amount of food and reduces weight. This drug improves the use of energy in the body and the process of burning fat. Also, silence increases the insulin sensitivity of the body, that is, the body reacts more effectively to insulin. The hunger control of silence is the third major impact. It feels full of stomach after eating, which reduces the desire to eat. When a person eats less and activity, then gradually his weight starts to lose.
Referring to the report of Lancet magazine, PM Modi said that by 2050, about 44 crore people in India will be affected by obesity problem, which is a serious challenge. About 40 percent of people in India are overweight, out of which 11.4 percent of people suffer from diabetes. According to a study published in The Lancet magazine, the world’s most populous countries are increasing obesity and diabetes cases in India and due to high obesity rate, India also comes in the worst three countries in the world. The Indian obesity drug market has increased five times since 2021 and its value is 6.28 billion rupees.
A government survey conducted from 2019 to 2021 found that 1 out of every 4 Indian adults suffer from overweight or obesity. 5 years ago this figure was one in every five. Given obesity only, the World Obesity Fetration has estimated that in 2023, the rate in Indian adults will be 8 percent, which is much lower than 22 percent in the US. But India has a population of 4 times more and the obesity rate in adults is estimated to increase by 11 percent by 2035.
